rethinkPeptides Search
Menu
Study breakdown

A Peptide Delivery System That Guides a Cancer Drug Directly to Tumors, Sparing Healthy Organs

AnimalModerate evidence
The takeaway

A peptide-drug conjugate called DiWB-1 delivers a PI3K cancer drug directly to LHRH-receptor-positive tumors, matching or beating the drug's anti-cancer activity while eliminating its liver, kidney, and blood sugar toxicity in mice.

Zero organ toxicity

DiWB-1 suppressed tumors in mice without the liver damage, kidney damage, or hyperglycemia caused by buparlisib alone — the peptide targeting eliminated off-target effects

What the researchers found

Researchers created DiWB-1, a peptide-drug conjugate that links an LHRH-receptor-targeting peptide to the PI3K inhibitor buparlisib. DiWB-1 was more potent than buparlisib alone against LHRH-receptor-positive breast cancer cells (IC50 of 1.8 μM vs 2.4 μM) while being less toxic to normal cells. In mice, DiWB-1 suppressed tumors effectively while avoiding the liver damage, kidney damage, and blood sugar spikes caused by buparlisib alone. The conjugate also showed favorable metabolic stability with a half-life of 5.6 hours, slightly longer than the established peptide drug triptorelin (4.2 hours).

Why it matters

PI3K inhibitors are effective against certain cancers but cause serious side effects because they hit healthy cells too. By attaching buparlisib to a peptide that homes in on LHRH receptors — which are overexpressed on many cancer types — the researchers created a drug that preferentially accumulates in tumors. This peptide-drug conjugate approach could make potent but toxic cancer drugs safer and more effective by delivering them directly to cancer cells.

The numbers in context

IC50: 1.8 μM (DiWB-1) vs 2.4 μM (buparlisib alone) · Half-life: 5.6h (DiWB-1) vs 4.2h (triptorelin) · No liver/kidney damage · No hyperglycemia · Reduced toxicity in normal cells

How the study worked

The researchers developed the LHRH-targeting peptide IV-6, characterized its receptor affinity and metabolic stability, then conjugated it to buparlisib to form DiWB-1. They tested anti-cancer activity in vitro against LHRH-receptor-positive MDA-MB-231 breast cancer cells and normal cells. In vivo efficacy was assessed in a mouse xenograft tumor model, with toxicity evaluated via organ histology and blood chemistry. Pharmacokinetic studies measured half-life and metabolic stability.

Who was studied

LHRH-receptor-positive breast cancer cells (in vitro) and tumor-bearing mice (in vivo)

What this study cannot tell us

This is preclinical research using a single cancer cell line (MDA-MB-231) and mouse xenograft models. The improvement in IC50 over buparlisib alone is modest (1.8 vs 2.4 μM). The study only tested LHRH-receptor-positive tumors; efficacy against receptor-negative cancers is unknown. Human pharmacokinetics and safety are not established. Manufacturing complexity and cost of the PDC are not discussed.

How to read the evidence

This is a well-designed preclinical study with both in-vitro and in-vivo data, including pharmacokinetics and toxicity evaluation. Published in Archiv der Pharmazie, it provides solid proof of concept but is limited to animal models with a single cancer cell line.

When this study was published

Published in 2025, this is very recent research in the rapidly growing field of peptide-drug conjugates for cancer therapy. Clinical translation would require several more years of development.

The bigger picture

Peptide-drug conjugates (PDCs) are an emerging class of targeted cancer therapy positioned between small-molecule drugs and the larger antibody-drug conjugates (ADCs). PDCs are smaller, cheaper to manufacture, and can penetrate tumors more easily than antibodies. LHRH-receptor targeting is particularly versatile because these receptors are overexpressed in breast, prostate, ovarian, and endometrial cancers. DiWB-1 demonstrates the practical promise of this approach — taking a drug with known efficacy but problematic toxicity and making it tumor-selective.

Questions still open

  • Would DiWB-1 be effective against other LHRH-receptor-positive cancers like prostate, ovarian, and endometrial tumors?
  • How does the cost and manufacturing complexity of this PDC compare to existing antibody-drug conjugates?
  • Could the LHRH-targeting peptide IV-6 be used to deliver other toxic chemotherapy drugs that are limited by side effects?

Common questions

What is a peptide-drug conjugate and how does it target cancer?
A peptide-drug conjugate (PDC) links a cancer-killing drug to a small peptide that acts as a homing device. The peptide recognizes and binds to specific receptors that are overexpressed on cancer cells but rare on normal cells. This delivers the toxic drug directly to the tumor, reducing damage to healthy organs. Think of it as a guided missile versus a bomb.
Why target LHRH receptors for cancer treatment?
LHRH receptors (luteinizing hormone-releasing hormone receptors) are overexpressed on the surface of many common cancers including breast, prostate, ovarian, and endometrial tumors, while being relatively rare on most normal tissues. This makes them an ideal target for directing cancer drugs specifically to tumor cells while sparing healthy organs.

Read the original research

DiWB-1: A Luteinizing Hormone Releasing Hormone (LHRH)-Targeted Peptide-Drug Conjugate (PDC) With Enhanced Tumor Selectivity and PI3K Inhibition Efficacy.

Archiv der Pharmazie, 358(6), e70021

Citation

Zhang, Chenyu; Zhong, Honglan; Li, Xiang; Xing, Zhenjian; Li, Siming; Yu, Rui; Deng, Xin. (2025). DiWB-1: A Luteinizing Hormone Releasing Hormone (LHRH)-Targeted Peptide-Drug Conjugate (PDC) With Enhanced Tumor Selectivity and PI3K Inhibition Efficacy.. Archiv der Pharmazie, 358(6), e70021. https://doi.org/10.1002/ardp.70021